[Response rate of AML-XH-99 protocol in the treatment of 82 childhood acute myeloid leukemia].
OBJECTIVE
To evaluate the outcomes of childhood acute myeloid leukemia (AML) treated with AML-XH-99 protocol and explore how to improve the event-free survival (EFS) rate.


METHODS
Eighty-two patients entered AML-XH-99 clinical trial. Survival rates were evaluated by Kaplan-Meier method with SPSS.


RESULTS
Among the 82 patients, 58 (70.7%) achieved complete remission (CR) after one course treatment, and the total CR rate was 84.1%. The overall 5 year EFS rate was (46.1 +/- 9.1)% and disease-free survival (DFS) rate was (54.3 +/- 10.3)% over a median observation period of 23 months. The 5 year EFS rate of 56 patients received high-dose cytarabine(HD-Ara-C) as intensification therapy was (47.2 +/- 12.9)%. Relapse occurred in 19 patients (26.0%) with a median time of 10 months (ranges 2 approximately 53 months), 28 patients died.


CONCLUSIONS
AML-XH-99 protocol resulted in a higher CR rate, especially one course CR rate, which was one of the key factors for long-term EFS and HD-Ara-C intensification therapy was effective in the treatment of childhood AML.
Li
Juan
J
Xin Hua Hospital/Shanghai Children's Medical Center, Shanghai Second Medical University, Shanghai 200127, China.
Gu
Long-Jun
LJ
Xue
Hui-Liang
HL
Tang
Jing-Yan
JY
Chen
Jing
J
Zhao
Hui-Jun
HJ
Chen
Jing
J
Pan
Ci
C
Wang
Yao-Ping
YP
Ye
Hui
H
D000293:Adolescent; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002648:Child; D002675:Child, Preschool; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007223:Infant; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D008297:Male; D016896:Treatment Outcome